Objective:To investigate the effects of metformin (MF) and vibration intervention on the improvement of bone mineral density (BMD) and glucose metabolism in diabetic rats with osteoporosis (DOP) .Methods:In this study, 125 rats were purchased, 100 rat models of diabetic osteoporosis were selected according to the random number table sampling method, and 100 rats were tested for modeling. According to the principle of random grouping, the rats successfully modeled were divided into model control groups (group MC) , metformin group (group MF) , vibration group (group V) , metformin + vibration group (group MV) . Normally fed 25 rats were blank control group (group C) . Rats in each group were treated for 20 weeks of intervention according to their own protocols. After the intervention, various samples were collected from rats in each group for BMD testing and HOME-IR testing.Results:Compared with the pre-measured BMD value of group C, the pre-measured BMD of group MC, group MF, group V and group MV were significantly reduced, respectively 0.21±0.03, 0.20±0.04, 0.20±0.03, 0.19±0.05 (g/cm 2) , P<0.05, indicating that the DOP model was successfully constructed. After 20 weeks of intervention, the BMD values of group MF, group V, and group MV were respectively 0.23±0.07, 0.24±0.05, 0.27±0.01 (g/cm 2) , significantly higher than the pre-measured value and the post-measured value of group MC, P<0.05. Comparing the changes in bone metabolism after the intervention of the patients, it was found that HOP of group MF, group V, and group MV after the intervention were 17.07±2.33, 16.95±4.22, and 15.43±3.75 (mg/g) respectively; DPD of group MF, group V and group MV were 3.26±0.09, 3.13±0.10, 2.95±0.10 (mmol/L) , respectively; The TRACP of the MF group, the V group and the MV group were 152.51±10.89, 149.67±11.05, and 143.90±10.67 (μg/L) respectively; The bone metabolism indexes of the patients were significantly lower than the pre-measured values and the post-measured values of the MC group, P<0.05. Comparing the glucose metabolism and insulin sensitivity of the patients after the intervention, it was found that FPG of group MF, group V, and group MV after the intervention were 15.32±4.98, 16.34±5.76, 19.76±5.71 (mmol/L) respectively. The FINS of group MF, group V and group MV were 25.46±6.21, 27.92±5.33, 29.85±7.22 (mmol/L) respectively. The HOME-IR of group MF, group V, and group MV were 17.39±1.37, 20.27±1.36, 26.81±1.83 (mmol/L) respectively, and all the indexes were significantly lower than those of group MC, P<0.05. Conclusion:This study believes that metformin and vibration intervention can significantly reduce blood glucose and relieve symptoms in diabetic rats with osteoporosis Insulin sensitivity, reduce bone loss, increase bone density.

OBJECTIVE: To explore the clinical effect of Li-Dan-He-Ji in the treatment of infantile cholestatic hepatic fibrosis. METHODS: Patients who met the diagnostic criteria of infantile cholestatic hepatic fibrosis in the department of integrated traditional Chinese and Western medicine and the department of gastroenterology of Wuhan Children's Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology from January to December 2021 were included in the study by prospective randomized controlled trial. They were divided into the conventional treatment group and Li-Dan-He-Ji group according to the random number table. The patients in the conventional treatment group were given conventional treatment according to the guidelines. In the Li-Dan-He-Ji group, the self-made Chinese medicinal compound Li-Dan-He-Ji (prescription: Herba Artemisiae Scopariae, Fructus Forsythiae, Radix et Rhizoma Rhei preparata, Radix Polygoni Multiflori Preparata, Radix Paeoniae Rubra, Ramulus Cinnamomi, Fructus Aurantii, Rhizoma Atractylodis Macrocephalae, Fructus Schisandrae Chinensis, Carapax Trionycis, and Radix Glycyrrhizae) was given on the basis of the routine treatment, by oral, enema or nasal feeding, 60 mL each day, divided into 2 or 3 times, for 28 days. Outpatient follow-up was maintained for 4 weeks. Before and after treatment, serum liver fibrosis 4 items [type IV collagen (IV-C), hyaluronidase (HA), type III procollagen (PC III), laminin (LN)], liver function and cholestasis-related markers [total bilirubin (TBil), direct bilirubin (DBil), total bile acid (TBA), alkaline phosphatase (ALP), γ-glutamyl transpeptidase (γ-GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST)], oxidative stress markers [superoxide dismutase (SOD), malondialdehyde (MDA), and glutathione (GSH)], liver stiffness measurement (LSM) detected by transient elastography (TE), aspartate aminotransferase-to-platelet ratio index (APRI), and liver and spleen retraction time were recorded in the two groups. RESULTS: During the observation period, a total of 40 cases of cholestatic hepatic fibrosis were treated, including 21 cases in the conventional treatment group and 19 cases in the Li-Dan-He-Ji group. Before treatment, the differences in serum liver fibrosis 4 items, serum liver function and cholestasis-related markers, oxidative stress indexes, LSM and APRI of the two groups were not statistically significant. After treatment, the liver fibrosis 4 items, liver function and cholestasis-related markers, LSM, and APRI were all significantly decreased in both groups, and the indexes in the Li-Dan-He-Ji group were significantly lower than those in the conventional treatment group [HA (ng/L): 165.81±21.57 vs. 203.87±25.88, PC III (μg/L): 69.86±9.32 vs. 81.82±7.39, IV-C (μg/L): 204.14±38.97 vs. 239.08±24.93, LN (μg/L): 162.40±17.39 vs. 190.86±15.97, TBil (μmol/L): 37.58±27.63 vs. 53.06±45.09, DBil (μmol/L): 20.55±19.34 vs. 30.08±27.39, ALP (U/L): 436.50±217.58 vs. 469.60±291.69, γ-GGT (U/L): 66.78±35.84 vs. 87.00±32.82, ALT (U/L): 64.75±50.53 vs. 75.20±50.19, AST (U/L): 77.25±54.23 vs. 96.80±59.77, TBA (μmol/L): 74.35±44.44 vs. 85.45±39.50, LSM (kPa): 5.24±0.39 vs. 7.53±3.16, APRI: 0.52±0.39 vs. 0.98±0.29, all P < 0.05]. After treatment, MDA in the two groups were significantly lower than those before treatment, and SOD and GSH were significantly higher than those before treatment. The level of SOD in the Li-Dan-He-Ji group was significantly higher than that in the conventional treatment group (kU/L: 64.56±6.69 vs. 51.58±5.98, P < 0.05). In addition, the liver retraction time (day: 20.13±10.97 vs. 24.33±13.46) and spleen retraction time (day: 25.93±13.01 vs. 29.14±14.52) in the Li-Dan-He-Ji group were significantly shorter than those in the conventional treatment group (both P < 0.05). CONCLUSIONS The use of Li-Dan-He-Ji in the treatment of cholestatic hepatic fibrosis can effectively improve the indicators of cholestasis, hepatic fibrosis, oxidative stress and clinical symptoms in children.
Child ; Humans ; Prospective Studies ; Cholestasis/pathology* ; Liver ; Liver Cirrhosis/drug therapy* ; Bilirubin/pharmacology* ; Oxidative Stress ; Aspartate Aminotransferases/metabolism* ; Superoxide Dismutase/metabolism*